Pfizer Inc. broke ground for its new biologics clinical manufacturing facility in Andover, Massachusetts with an investment of $200 Million.
The New 175,000 sq. ft. state-of-the-art facility that will enable the production of high-quality, complex biologics and vaccines. The new 5-story building is expected to be operational by January 2019. Approximately 75 new employees will be hired to support clinical manufacturing. In addition to the Andover campus, Massachusetts is home to Pfizer’s Research and Development hub in Cambridge. Pfizer has approximately 2,000 employees based in Massachusetts.
The new clinical manufacturing facility is designed with 5 independent manufacturing suites to support Pfizer’s highly complex and diverse biologics research effort. The facility will:
• Employ flexible design to fully enable Next Generation Manufacturing strategies.
• Leverage state-of-the-art single-use bioreactors and disposable process technologies.
• Provide clinical manufacturing options with the lowest cost and greatest flexibility for efficiently driving important clinical drugs to patients.
|Type||New Biologics Clinical Manufacturing Facility|
|Estimated Cost||$200 Million|
|Operational By||January 2019|